Adenocarcinoma of the prostate with small cell component and low levels of prostate specific antigen

Saša  Vojinov; Mladen Popov; Ivan Levakov; Aleksandra Levakov Fejsa; Dimitrije Jeremić; Dragan Grbić

doi:10.2298/VSP181212029V

Saša Vojinov University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Mladen Popov University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Ivan Levakov University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Aleksandra Levakov Fejsa Clinical Center of Vojvodina, Department of Urology,Novi Sad, Serbia
Dimitrije Jeremić University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Dragan Grbić Clinical Center of Vojvodina, Department of Urology, Novi Sad, Serbia

DOI: https://doi.org/10.2298/VSP181212029V

Keywords: prostatic neoplasms, prostate-specific antigen, diagnostic techniques and procedures, prostatectomy, drug therapy, prognosis

Abstract

Introduction. Prostate cancer is one of the most common malignancies in men. The most common type is acinar adenocarcinoma. Small cell prostate cancer (SCPC) usually occurs together with coexisting prostate adenocarcinoma. Case report. A 72-years-old patient with voiding simptoms is presented. Initial level of prostate specific antigen (PSA) was 2.87 ng/mL. Twelve prostate biopsies were taken and in six of them neoplastic tissue was detected. The viewed tissue was most convenient to “small cell carcinoma“. Bone scintigraphy did not demonstrate dissemination of the cancer into the skeletal system. Multislice computed tomography (MSCT) of the pelvis did not reveal any special pathological changes. The patient underwent surgery – radical retropubical prostatectomy. Histopathological analysis revealed a poorly differentiated adenocarcinoma of the prostate with small cell carcinoma zones [Gleason score 5+5 (10), grade III, pT3bN1, stage IV]. Conclusion. Poorly differentiated adenocarcinoma of the prostate, especially in combination with SCPC, is an aggressive malignancy with most cases presenting with the extensive disease dissemination on diagnosis and poor prognosis. Small cell carcinomas of the prostate are extremely rare tumors of the neuroendocrine origin. Patients with mixed prostate cancer, compared to pure SCPC, have a better prognosis and greater survival rate. There is a lack of the evidence guiding treatment for SCPC.

References

Nwaneri AC, McBeth L, Hinds TD Jr. Prostate Cancer in Afri-can American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling. Horm Cancer 2016; 7(5–6): 296–304.

Têtu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinico-pathologic study of 20 cases. Cancer 1987; 59(10): 1803–9.

Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. On-cology (Williston Park) 2014; 28(10): 831–8.

Palmgren JS, Karavadia SS, Wakefield MR. Unusual and un-derappreciated: small cell carcinoma of the prostate. Semin Oncol 2007; 34(1): 22–9.

Abbas F, Civantos F, Benedetto P, Soloway MS. Small cell carci-noma of the bladder and prostate. Urology 1995; 46(5): 617–30.

Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology 2012; 60(1): 59–74.

Farach A, Ding Y, Lee M, Creighton C, Delk NA, Ittmann M, et al. Neuronal Trans-Differentiation in Prostate Cancer Cells. Prostate 2016; 76(14): 1312–25.

Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spec-trum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book 2015: 92–103.

Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973–2003: a population-based study. BJU Int 2012; 109(6): 824–30.

Wenk RE, Bhagavan BS, Levy R, Miller D, Weisburger W. Ec-topic ACTH, prostatic oat cell carcinoma, and marked hyper-natremia. Cancer 1977; 40(2): 773–8.

Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A et al. Results of a phase II study with doxorubicin, etopo-side, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20(14): 3072–80.

Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992; 147(3 Pt 2): 935–7.

Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term out-comes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013; 64(2): 307–13.

Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mos-quera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30(36): e386–9.

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene am-plifications are harbingers of lethal treatment-related neuro-endocrine prostate cancer. Neoplasia 2013; 15(1): 1–10.